Latest news with #medicaldevice
Yahoo
16 hours ago
- Business
- Yahoo
CooperCompanies (COO) Stock Trades Up, Here Is Why
What Happened? Shares of medical device company CooperCompanies (NASDAQ:COO) jumped 3.4% in the morning session after analysts at BNP Paribas Exane upgraded the stock. The firm raised its rating on CooperCompanies from "neutral" to "outperform" and increased its price target to $92 from $76. This new target suggests a potential upside of nearly 29% from the stock's previous closing price. An analyst upgrade from a notable financial institution can often boost investor confidence by signaling a positive outlook on the company's future performance. After the initial pop the shares cooled down to $72.78, up 2% from previous close. Is now the time to buy CooperCompanies? Access our full analysis report here, it's free. What Is The Market Telling Us CooperCompanies's shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was about 2 months ago when the stock dropped 15% on the news that the company reported underwhelming first-quarter 2025 results (fiscal Q2), with sales exceeding expectations by a whisker while organic sales growth guidance for the full year was lowered. Management called out "softening in two of its growth markets, contact lenses and fertility." On a brighter note, COO raised its full-year revenue and EPS guidance, off the back of the modest beat. In addition, its organic revenue and EPS outperformed Wall Street's estimates during the quarter. Overall, this print had some key positives. Investors were likely hoping for more. CooperCompanies is down 19.7% since the beginning of the year, and at $72.78 per share, it is trading 34.6% below its 52-week high of $111.23 from September 2024. Investors who bought $1,000 worth of CooperCompanies's shares 5 years ago would now be looking at an investment worth $1,005. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.


Globe and Mail
19 hours ago
- Business
- Globe and Mail
Is Hologic Stock a Risky Investment Ahead of Its Q3 Earnings Report?
Hologic HOLX is set to release third-quarter fiscal 2025 results on July 30, after the closing bell. The Zacks Consensus Estimate for third-quarter earnings per share (EPS) suggests a 0.9% decrease year over year to $1.05. The estimate has dropped by 1 cent in the past 60 days. The Zacks Consensus Estimate for third-quarter revenues currently stands at $1.01 billion, suggesting a 0.4% decline year over year. The U.S. medical device maker focusing on women's health has a mixed record over the trailing four quarters. It topped estimates in three quarters and missed on one occasion. On average, the earnings surprise came in at 1.23%. Q3 Earnings Whispers for HOLX Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here. Earnings ESP: Hologic has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks Rank #1 stocks here. Factors Shaping Hologic's Q3 Performance Starting with the largest division, Diagnostics' performance in the fiscal third quarter may have been mixed. Molecular Diagnostics is expected to have favorably impacted revenues, with the BV/CV/TV assay being a key contributor. Hologic has been working to drive awareness and reimbursement of the test to address a large unmet need in the U.S. vaginitis market. The Biotheranostics oncology business is likely to have continued to benefit from the ongoing adoption of the Breast Cancer Index ('BCI') test. However, the loss of the HIV testing business in Africa following the halt of USAID funding is expected to have weighed on growth. In cytology and perinatal businesses, Hologic is likely to have witnessed the robust U.S. adoption of the Genius AI product. Meanwhile, international performance is expected to have suffered, particularly due to ongoing headwinds in China. Tariffs, increasing local competition and rising anti-American sentiment, along with more available alternatives, are expected to affect overall segment results. Our model forecasts a 1.1% decline year over year in Diagnostics revenues to $436 million. We also expect the company's Breast Health segment to sustain the recent downward trend from lower capital equipment sales. However, recurring service revenues — tied to Hologic's large installed base — may have helped offset some declines. Endomagnetics is likely to have entered the second half of the year with strong momentum, positively contributing to the Interventional Breast portfolio. Still, tariffs are expected to have posed challenges as a bulk of these products are manufactured outside the United States. According to our model, Breast Health revenues in the fiscal third quarter are likely to decrease 4.7% year over year to $366.8 million. Similarly, the GYN Surgical segment also may have faced tariff pressure in the fiscal third quarter, given that a majority of these products are made in Costa Rica. Despite that, robust international sales are likely to have supported growth. The Fluent Pro Fluid Management System may have continued gaining traction. Further, ongoing integration of the newly acquired Gynesonics is expected to have positively contributed to Hologic's revenues in the to-be-reported quarter. Our model forecasts Surgical division revenues to improve 6.4% year over year to $177.3 million. Further, Hologic's production ramp-up of the Horizon DXA system in Skeletal Health in the second quarter is likely to have been carried into the to-be-reported quarter as well. Our model estimates 40.2% growth in the Skeletal business, reaching $26.6 million. HOLX Stock Price Performance & Valuation In the past year, Hologic shares have declined 18.5%, steeper than the industry's 15.7% fall and the Zacks Medical sector's 17.6% drop. The company also underperformed peers Abbott ABT and QIAGEN QGEN, which have risen 19.6% and 12.8%, respectively. HOLX One-Year Price Comparison Valuation-wise, Hologic is trading at a forward five-year Price/Sales (P/S) of 3.35X, lower than the industry average of 4.01X. The stock is graded a Value Score of B at present. HOLX 5-Year P/S Ratio Hologic's Investment Consideration Hologic continues to yield robust growth and durability, benefiting from its presence in both Diagnostics and Medtech. Across each of its franchises, the company offers products that are widely recognized and often seen as the standard of care, such as ThinPrep and cervical cancer screening on Panther instrument in Molecular Diagnostics, 3D Genius mammography in Breast Health business and MyoSure for the treatment of fibroids in the Surgical business. Hologic's international business also drives strong top-line performance, reflecting its ability to capture potential opportunities into reality. Backed by a strong balance sheet and disciplined approach to capital allocation, the company continues to strengthen its foundation with acquisitions like Endomagnetics and Gynesonics. That said, Hologic remains exposed to macroeconomic volatility. Tariffs tied to its manufacturing activities in Costa Rica and China could increase inventory acquisition costs by $20-$25 million per quarter in fiscal 2025, pressuring margins. The company reduced its China revenue forecast by $20 million amid tougher operating conditions, now projecting only $50 million. Further, currency headwinds forecasted for this year are approximately $10-$15 million. Hologic expects a low-single-digit decline in Breast Health, while Diagnostics growth is expected to be limited by Africa weakness and lower sales in China. How to Play HOLX Stock? Hologic's weak top and bottom-line projections for the fiscal third quarter, together with industry and broader macroeconomic challenges weighing on business segments, are likely to continue dragging its stock performance. While the company has several key drivers that promise long-term growth, including valuable inorganic additions, its near-term headwinds warrant a more cautious stance. Hence, at this stage, HOLX stock may not present a favorable entry point. Those already invested may find it wise to exit. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Abbott Laboratories (ABT): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report QIAGEN N.V. (QGEN): Free Stock Analysis Report


Globe and Mail
20 hours ago
- Business
- Globe and Mail
Autonomix Medical, Inc. Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. For the event, Mr. Hauser dove deeper into his dedication to the Company, how he got to where he is today, and provided insight into why he is passionate about the Company's innovative technology. The on-demand video webcast is now available on the Virtual Investor website as well as the Events page under the Investors section of the Company's website ( About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. For more information, visit and connect with the Company on X, LinkedIn, Instagram and Facebook. Investor and Media Contact JTC Team, LLC Jenene Thomas 908.824.0775 autonomix@ This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Yahoo
20 hours ago
- Business
- Yahoo
Autonomix Medical, Inc. Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. For the event, Mr. Hauser dove deeper into his dedication to the Company, how he got to where he is today, and provided insight into why he is passionate about the Company's innovative technology. The on-demand video webcast is now available on the Virtual Investor website as well as the Events page under the Investors section of the Company's website ( About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. For more information, visit and connect with the Company on X, LinkedIn, Instagram and Facebook. Investor and Media ContactJTC Team, LLCJenene Thomas908.824.0775autonomix@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 hours ago
- Business
- Yahoo
Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales
Company Continues to Strengthen Organizational Infrastructure with Success-Driven Medical Device Veteran Christina Bailey, VP of Sales, Microbot Medical HINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales. A two-time U.S. Olympian with 20 years of medical device sales experience, Ms. Bailey has successfully led commercial teams to achieve sales goals. She will report directly to Harel Gadot, the Company's CEO, President and Chairman. Ms. Bailey has held a variety of sales leadership roles. She has worked with notable companies like Boston Scientific, Abbott, Stryker and Intuitive Surgical that have equipped her with the insights necessary to drive growth and innovation. As the Vice President of US Sales at Endologix, her leadership in building and scaling the sales team while achieving sales milestones demonstrate her capability to lead crucial product launches. Ms. Bailey serves as a Board Member for USA Hockey. As a member of the U.S.A. Women's Hockey Team, she won a gold medal at the 1998 Winter Olympics held in Nagano, Japan. 'Christina is a sales leader with a track record of building and working within high-performing teams across her professional and Olympic careers,' commented Mr. Gadot. 'We believe her leadership will strengthen our commercial efforts as she begins establishing an experienced and mission-driven sales team to support our anticipated launch of LIBERTY.' LIBERTY is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the U.S. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. Further information about Microbot Medical® is available at Safe Harbor Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as 'contemplates,' 'continues,' 'could,' 'forecasts,' 'intends,' 'may,' 'might,' 'possible,' 'potential,' 'predicts,' 'projects,' 'should,' 'would,' 'will,' 'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates' and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading 'Risk Factors' in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law. Investor Contact: IR@ A photo accompanying this announcement is available at in to access your portfolio